{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:11:25Z","timestamp":1753355485524},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,6,26]],"date-time":"2007-06-26T00:00:00Z","timestamp":1182816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Photoderm Photoimm Photomed"],"published-print":{"date-parts":[[2007,8]]},"abstract":"<jats:p><jats:bold>Purpose: <\/jats:bold> The aim of the study was to examine the tumour necrosis factor \u03b1 (TNF\u2010\u03b1)\u2010converting enzyme (TACE) concentration in peripheral blood mononuclear cells (PBMC) and its relationship with plasma concentration of soluble TNF\u2010\u03b1 receptor type 1 (sTNF\u2010R1) and with the disease severity in psoriasis patients treated with narrowband ultraviolet B (NB\u2010UVB).<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> The study has been conducted among 40 patients with plaque\u2010type psoriasis vulgaris: 23 had only skin lesions (PV) and 17 had co\u2010existing, inactive, psoriatic arthritis (PsA). Control blood samples were obtained from 20 healthy subjects. The assessment of the severity of skin lesions (using Psoriasis Area and Severity Index \u2013 PASI), TACE and sTNF\u2010R1 concentrations (using quantitative sandwich enzyme immunoassays) have been performed at baseline (T 0) and after 20 NB\u2010UVB irradiations (T 20).<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> The baseline sTNF\u2010R1 and TACE concentrations in all patients was higher than that in controls (2.55 \u00b1 1.67 vs. 1.70 \u00b1 0.15\u2003ng\/ml, <jats:italic>P<\/jats:italic>&lt;0.001, respectively, and 2.62 \u00b1 0.32 vs. 1.31 \u00b1 0.30\u2003ng\/ml, <jats:italic>P<\/jats:italic>&lt;0.001, respectively). The sTNF\u2010R1 and TACE concentrations were lower in PV than in PsA patients (2.47 \u00b1 0.16 vs. 2.65 \u00b1 0.13\u2003ng\/ml, and 2.52 \u00b1 0.22 vs. 2.76 \u00b1 0.39\u2003ng\/ml, <jats:italic>P<\/jats:italic>&lt;0.05, respectively). The baseline PASI correlated with sTNF\u2010R1 and to TACE concentrations (<jats:italic>R<\/jats:italic>=0.48 and 0.39, <jats:italic>P<\/jats:italic>&lt;0.05, respectively). The sTNF\u2010R1 correlated to TACE concentration (<jats:italic>R<\/jats:italic>=0.52, <jats:italic>P<\/jats:italic>&lt;0.05). The significant decline in sTNF\u2010R1 and TACE concentrations at T 20 was noticed, TACE reached control values (1.20 \u00b1 0.44\u2003ng\/ml in PV patients and 1.16 \u00b1 0.48\u2003ng\/ml in PsA patients, respectively).<\/jats:p><jats:p><jats:bold>Conclusion: <\/jats:bold> TACE from PBMC can contribute to up\u2010regulation of sTNF\u2010R1 in patients with active psoriasis vulgaris and with psoriatic arthritis. It also can serve as a sensitive marker of the disease severity.<\/jats:p>","DOI":"10.1111\/j.1600-0781.2007.00296.x","type":"journal-article","created":{"date-parts":[[2007,6,26]],"date-time":"2007-06-26T13:19:39Z","timestamp":1182863979000},"page":"130-134","source":"Crossref","is-referenced-by-count":18,"title":["Tumour necrosis factor \u03b1 (TNF\u2010\u03b1)\u2010converting enzyme (TACE) and soluble TNF\u2010\u03b1 receptor type 1 in psoriasis patients treated with narrowband ultraviolet B"],"prefix":"10.1111","volume":"23","author":[{"given":"Agnieszka Beata","family":"Serwin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Sokolowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bozena","family":"Chodynicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,26]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004030050299"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/385733a0"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/385729a0"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06440.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.19.14608"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.175.2.323"},{"key":"e_1_2_5_8_2","first-page":"145","article-title":"Role of increased production of monocytes TNF\u2010\u03b1, IL\u20101\u03b2 and IL\u20106 in psoriasis","volume":"14","author":"Mizutani H","year":"1997","journal-title":"relation to focal infection, disease activity and responses to treatments"},{"key":"e_1_2_5_9_2","first-page":"113","article-title":"TNF\u2010R and IL\u20106R transmembrane recptors expression and release of their soluble forms by neutrophils and mononuclear cells from cancer patients","volume":"46","author":"Jablonska E","year":"2001","journal-title":"Rocz Akad Med Bialymst"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2005.00164.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2005.00162.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(73)90035-8"},{"key":"e_1_2_5_13_2","first-page":"238","article-title":"Severe psoriasis","volume":"157","author":"Fredriksson T","year":"1978","journal-title":"oral therapy with a new retinoid"},{"key":"e_1_2_5_14_2","first-page":"354","article-title":"Localisation of tumor necrosis factor alpha (TNF\u2010alpha) and its receptors in normal and psoriatic skin","volume":"94","author":"Kristensen M","year":"1993","journal-title":"epidermal cells express the 55-kD but not the 75-kD TNF receptor"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030338"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20040229"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ALC.0000139819.46514.06"}],"container-title":["Photodermatology, Photoimmunology &amp; Photomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0781.2007.00296.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0781.2007.00296.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T15:27:17Z","timestamp":1697038037000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0781.2007.00296.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,26]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["10.1111\/j.1600-0781.2007.00296.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0781.2007.00296.x","archive":["Portico"],"relation":{},"ISSN":["0905-4383","1600-0781"],"issn-type":[{"value":"0905-4383","type":"print"},{"value":"1600-0781","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,26]]}}}